Business Wire

Ingenico TravelHub Opens up New Payments Routes for Travel Companies

30.7.2019 10:30:00 EEST | Business Wire | Press release

Share

Ingenico Group (Euronext: FR0000125346 - ING), the global leader in seamless payments has launched TravelHub, a solution built to connect travel companies with Ingenico’s global end-to-end payment processing capabilities and regional gateways across Asia, Latin America and Europe.

TravelHub allows travel companies to easily access more than 150 payment methods – including credit cards and alternative payment solutions - and currency options relevant for their customers. It offers smart transaction routing capabilities across all payment platforms, improving conversion rates and, as a result, increasing revenue from online travel sales.

Ingenico’s TravelHub offers a simple direct connection to global payment capabilities, as well as integration with the leading airline global distribution systems (GDS), such as Amadeus, Sabre and Navitaire, and hotels’ property management systems (PMS). This helps travel businesses tackle the complexity of managing multiple systems, payment service providers (PSPs) and acquirers.

The sophisticated solution marks Ingenico’s increased focus on travel, an industry where it already celebrates a strong portfolio and a long history of working with some of the world’s most famous airlines, hotels and online travel agents (OTAs). It is built by a dedicated team of seasoned professionals from the travel payments industry, and this combination of technology and expertise positions Ingenico to help travel companies grow and expand globally.

Kevin Weber, Chief Projects Officer and Chief Information Officer at Viva Air, who has been using TravelHub already, said: “Ingenico’s TravelHub helped us to increase authorization rates and revenue significantly, and supported our expansion to new countries.”

Gabriel de Montessus, SVP Global Online for Ingenico Group, said: “We are very proud to be launching TravelHub, a state of the art solution that helps travel companies increase revenue from online channels. TravelHub combines the global reach of Ingenico’s online payment platforms that can now be accessed with a simple connection.”

Eric Liebman, Global Head of Travel at Ingenico ePayments, said: “Online travel businesses are looking to navigate the complex technology ecosystem while growing quickly in a very competitive space. TravelHub helps travel companies provide the best digital customer experience, offering payment methods and currencies travellers want to pay with.”

As the solution continues to gain popularity among travel businesses, ongoing developments will be made to add new travel technology connections and improve direct connections, making it easier to access new markets.

- ENDS -

About Ingenico Group

Ingenico Group (Euronext: FR0000125346 - ING) is the global leader in seamless payment, providing smart, trusted and secure solutions to empower commerce across all channels, in-store, online and mobile. With the world’s largest payment acceptance network, we deliver secure payment solutions with a local, national and international scope. We are the trusted world-class partner for financial institutions and retailers, from small merchants to several of the world’s best known global brands. Our solutions enable merchants to simplify payment and deliver their brand promise.

www.ingenico.com twitter.com/ingenico

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ingenico ePayments / PR
Dylan Prins
Communications Manager, Global Online, Ingenico Group
Dylan.prins@ingenico.com
+31 (0) 6 12 15 80 03

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye